Elevated Serum Bile Acids Predict Poor Liver Outcomes in Children With Alagille Syndrome: Results From the GALA Study Group
Open Access
- 18 November 2025
- journal article
- Published by Wiley in Liver International
- Vol. 45 (12) , e70423
Abstract
Background and Aim: Alagille syndrome (ALGS) is a rare disorder characterised by cholestasis and extrahepatic manifestations. Given the current era of ileal bile acid transporter (IBAT) inhibitor therapies that reduce serum bile acid (SBA) levels, we evaluated whether SBA predicts liver disease outcomes in ALGS. Methods: Patients were ascertained from the G lobal AL agille A lliance (GALA) cohort. A prognostic threshold of SBA 102 μmol/L was assessed as a time‐dependent covariate in Cox regression analyses for native liver survival (NLS) and event‐free survival (EFS), while adjusting for total bilirubin (TB) levels. Results: 570 GALA patients were included (348 [61%] male). There was a moderate positive correlation between SBA and TB (Pearson correlation = 0.47, p < 0.001). SBA below 102 μmol/L was a significant predictor of outcomes (NLS: HR = 3.78, 95% CI 2.39–5.99, p < 0.001; EFS: HR = 3.44, 95% CI 2.35–5.04, p < 0.001). SBA remained a significant predictor for improved EFS after adjusting for TB clearance at 1 year (TB < 2 mg/dL; HR = 2.00, 95% CI 1.10–3.65, p = 0.02). Median SBA in the first year of life above 102 μmol/L, predicted lower NLS (67.2% vs. 83.5% at 7 years p = 0.05) and EFS (63.4% vs. 80.9% at 7 years, p = 0.02). Conclusion: Lower SBA in children with ALGS liver disease predicts improved NLS and EFS. SBA is also associated with NLS in children with ALGS who clear their bilirubin, that is, those with anicteric cholestasis. Although the patients studied here did not receive IBAT inhibition, these data suggest that lowering SBA may improve important clinical outcomes.Keywords
Funding Information
- Ipsen Biopharmaceuticals
- Alagille Syndrome Alliance
- National Natural Science Foundation of China (81873543)
- National Natural Science Foundation of China (81570468)
This publication has 7 references indexed in Scilit:
- Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trialThe Lancet Gastroenterology & Hepatology, 2024
- Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitorHepatology, 2023
- Serum bile acids as a prognostic biomarker in biliary atresia following Kasai portoenterostomyHepatology, 2023
- Natural history of liver disease in a large international cohort of children with Alagille syndrome: Results from the GALA studyHepatology, 2022
- Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 studyThe Lancet, 2021
- Genotype correlates with the natural history of severe bile salt export pump deficiencyJournal of Hepatology, 2020
- Clinically Evident Portal HypertensionJournal of Pediatric Gastroenterology and Nutrition, 2019